fbpx

Do you want to help reduce the risk of

HIV-1 infection?

Learn about a no-cost research study to examine novel implementation strategies and resources to support African American/Black cisgender and transgender women in the administration of APRETUDE, an FDA-approved injectable Pre-Exposure Prophylaxis (PrEP) medication that is used to lower the risk of sexually acquired HIV-1 infection.

Computer generated image of an emerging virus

Are you ready to make a difference in reducing the risk of HIV-1 infection?

Reducing the risk of HIV-1 infection is a critical health goal. Effective strategies include practicing safe sex using condoms, engaging in lower-risk sexual behaviors, taking pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) medications, and ensuring regular HIV testing. However, there is still a risk of contracting HIV, and barriers may prevent some people from accessing preventative care and treatment.

This clinical study aims to overcome the existing disparities in HIV pre-exposure prophylaxis (PrEP) by advancing the understanding of effective implementation strategies for PrEP medications and increasing awareness and usage among African American/Black cisgender and transgender women who have been prescribed APRETUDE for HIV-1 prevention.

If you are an African American/Black cisgender or transgender woman, you may be eligible to participate in a research study conducted at select centers across the U.S. There will be no cost if you qualify and choose to participate.

FILL OUT THE FORM BELOW IF YOU MEET THE FOLLOWING CRITERIA

  • Are 18 years of age or older
  • Are female at birth or self-identified transgender female
  • Are African American/Black
  • Are negative for HIV-1

About the Study

This research study is seeking African American/Black cisgender and transgender women who have been prescribed APRETUDE for the prevention of HIV-1 infection. APRETUDE is an FDA-approved, long-acting injection for Pre-Exposure Prophylaxis (PrEP) designed to reduce the risk of sexually acquired HIV-1. It is administered monthly by your health provider for the first two months and then every two months thereafter.

The study aims to learn about your experience in starting and receiving APRETUDE injections to develop strategies that can help individuals at higher risk of HIV-1 acquisition to understand, start, and maintain HIV pre-exposure prophylaxis (PrEP) medications. The study includes questions about your interactions with medical providers, the ease of use of the medication, and understanding and awareness of HIV prevention and PrEP medications.

The clinical trial will last approximately 12 to 13 months and will include trial-related medical examinations, surveys, laboratory work, and assessments by medical investigators. There will be no cost associated with participation in the trial. Your health insurance provider may cover the cost of APRETUDE, and you may receive compensation for your time to participate.

Computer generated image of an emerging virus

Why Participate?

If you are an African American/Black cisgender or transgender woman who is reducing the risk of HIV with APRETUDE, you may qualify for a new research study, now being offered at select centers throughout the U.S.

No-cost Study Care

You will receive study-related care from experienced doctors, nurses, and research staff.

Exams

The study will include physical examinations, surveys, laboratory work, and other assessments with a trained investigator.

COMPENSATION

You might be eligible to receive compensation for your time and travel.

Chat With a Research Coordinator

Fill out the form below, and you will be advised if you are eligible or not. If you meet the initial screening criteria, you will be contacted by someone from a research location near you. If you do not meet the minimum criteria, please still submit the form. The study criteria may change in the future, and you might become eligible later.

© 2024 Accelerate Recruitment | Privacy Policy | Legal Notice